Life Sciences Tools and Services
Company Overview of RainDance Technologies, Inc.
RainDance Technologies, Inc. develops genomic tools for non-invasive liquid biopsy applications for the research, early detection, and treatment of cancer, and other inherited and infectious diseases. It offers RainDrop, a digital polymerase chain reaction platform that generates picoliter-sized droplets for multiplex detection of HIV, DNA, or RNA; and consumables, such as source chips and sense chips, and oil surfactants. The company provides ThunderStorm, an automated next-generation sequencing (NGS) content enrichment solution that enables researchers to process various samples per day and generate quality data; ThunderBolts, a NGS panel for profiling important cancer mutations; ThunderBo...
749 Middlesex Turnpike
Billerica, MA 01821
Founded in 2004
Key Executives for RainDance Technologies, Inc.
Chief Executive Officer, President and Director
Co-Founder and Chief Technology Officer
Compensation as of Fiscal Year 2014.
RainDance Technologies, Inc. Key Developments
RainDance Technologies, Inc. Announces the Launch and Availability of the ThunderBolts Next-Generation Sequencing Target Enrichment System
Feb 25 15
RainDance Technologies, Inc. announced the launch and availability of the ThunderBolts Next-Generation Sequencing (NGS) Target Enrichment System. The ThunderBolts System enables researchers to rapidly detect and cost-effectively analyze somatic mutations from liquid biopsy samples (circulating tumor DNA) or precious FFPE (formalin-fixed Paraffin-Embedded) tissue samples. RainDance recently showcased the new ThunderBolts System and performance data at the International Molecular Medicine Tri-Conference, and will highlight the ThunderBolts System at the upcoming Advances in Genome Biology and Technology Meeting. The ThunderBolts System is a fast, accurate and low-cost NGS target enrichment system that features award-winning instrumentation and pre-validated gene panels for profiling solid tumors and hematological cancers, as well as flexible `open source' options for the generation of custom gene panels. The ThunderBolts System features the streamlined RainDance DirectSeq primer design and amplification method, which eliminates library preparation steps, minimizes off-target sequencing, and triples the sample capacity per sequencing run, resulting in significant throughput, batching, turnaround time, and cost advantages. The ThunderBolts System provides researchers the ability to confidently detect somatic or hematologic tumor mutations with frequencies as low as 1%, starting with as little as 10 ng of amplifiable DNA., Scientists can use the ThunderBolts System to research and screen for low-frequency mutations and then orthogonally validate and track these mutations with the ultrasensitive RainDrop® Digital PCR System, as they utilize the same core droplet technology platform. In addition, all current RainDrop systems are enabled to run ThunderBolts NGS panels to further extend their versatility and value. The RainDrop and ThunderBolts Systems are research-use-only tools.
RainDance Technologies, Inc. Announces Board Appointments
Nov 3 14
RainDance Technologies, Inc. announced the appointment of Martin M. Coyne II and Glenn P. Muir to its Board of Directors. Mr. Coyne currently serves as a director of Akamai, a role he has held since November 2001 and serves as Chairman of the Board of RockTech. Mr. Muir was Hologic's Chief Financial Officer from 1992 to May 2014 and Executive Vice President since 2000 with a broad range of financial and operating responsibilities including the oversight of the company's strategic initiatives.
RainDance Technologies Names John Luckey as Vice President of Product Development
Oct 15 14
RainDance Technologies has appointed John Luckey, Ph.D., as its new vice president of product development. Dr. Luckey brings more than 20 years of experience leading teams tasked with developing biotechnology systems and technology platforms. During his career, he has held senior product and
platform development positions in companies including Roche NimbleGen, where he directed research and development activities for improving and expanding the company's core DNA microarray synthesis technology and related instrumentation. Dr. Luckey also managed product development and engineering activities at MJ Research, contributing to the design and development of the Opticon product family and Opticon Monitor software.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|